Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter Phase Ib/II study of 9MW2821 plus other anti-tumor drugs in advanced gynecologic malignancies
CTR20250996Phase 2Active
- Sponsor
- Mabwell
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bulumtatug fuvedotin in cervical cancer (mCC), ovarian cancer, endometrial cancer (EC), sponsored by Mabwell. Started Apr 2025; status: active.
02
Drugs
bulumtatug fuvedotin
03
Conditions
cervical cancer (mCC)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on CTR20250996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250996.